Connect
MJA
MJA

Australasian Society for Infectious Diseases guidelines for the diagnosis and treatment of Clostridium difficile infection

Allen C Cheng, John K Ferguson, Michael J Richards, Jennifer M Robson, Gwendolyn L Gilbert, Alistair McGregor, Sally Roberts, Tony M Korman and Thomas V Riley
Med J Aust 2011; 194 (7): 353-358.
  • Allen C Cheng1,2
  • John K Ferguson3,4
  • Michael J Richards5,6
  • Jennifer M Robson7
  • Gwendolyn L Gilbert8
  • Alistair McGregor9
  • Sally Roberts10
  • Tony M Korman11
  • Thomas V Riley12,13

  • 1 Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC.
  • 2 Infectious Diseases Unit, Alfred Hospital, Melbourne, VIC.
  • 3 John Hunter Hospital, Newcastle, NSW.
  • 4 University of Newcastle, Newcastle, NSW.
  • 5 Victorian Infectious Diseases Service, Royal Melbourne Hospital, Melbourne, VIC.
  • 6 University of Melbourne, Melbourne, VIC.
  • 7 Sullivan Nicolaides Pathology, Brisbane, QLD.
  • 8 Centre for Infectious Diseases and Microbiology, Institute of Clinical Pathology and Medical Research, Sydney, NSW.
  • 9 Royal Hobart Hospital, Hobart, TAS.
  • 10 Clinical Microbiology Laboratory, LabPlus, Auckland District Health Board, Auckland, NZ.
  • 11 Infectious Diseases, Monash Medical Centre, Melbourne, VIC.
  • 12 Microbiology and Immunology, University of Western Australia, Perth, WA.
  • 13 Division of Microbiology and Infectious Diseases, PathWest Laboratory Medicine WA, Perth, WA.

Correspondence: allen.cheng@monash.edu

Acknowledgements: 

We thank Anton Peleg, Paul Johnson, Chris Lemoh, Kate Cherry, Gerhard Weldhagen, Craig Boutlis, Helen Van Gessel, Raymond Chan, Karen Rowland, David Mitchell and Gillian Wood for comments on an earlier draft of the guidelines. We also thank Ian Civil, Deirdre Mansell and Michael Grigg at the Royal Australasian College of Surgeons for their review.

Competing interests:

Allen Cheng received support from the Australian Commission for Safety and Quality in Healthcare for travel to present these guidelines. Tony Korman is on the advisory boards of Pfizer, AstraZeneca, Janssen-Cilag and Novartis, and has received payment for speaking at a Novartis-sponsored symposium in 2010 and for chairing meetings for Novartis and Janssen-Cilag in 2009. Thomas Riley has been on the advisory boards of Merck and Genzyme in relation to C. difficile treatment, is involved in research evaluating products in relation to C. difficile diagnosis and treatment that is funded by Bayer, bioMérieux, Becton Dickinson and Oxoid, and has received speakers’ fees from these companies.

  • 1. Viscidi R, Willey S, Bartlett JG. Isolation rates and toxigenic potential of Clostridium difficile isolates from various patient populations. Gastroenterology 1981; 81: 5-9.
  • 2. Boyce JM, Ligi C, Kohan C, et al. Lack of association between the increased incidence of Clostridium difficile-associated disease and the increasing use of alcohol-based hand rubs. Infect Control Hosp Epidemiol 2006; 27: 479-483.
  • 3. Elliott B, Thean S, Chang BJ, Riley TV. Molecular epidemiology of Clostridium difficile in Australia [abstract]. In: Clostridia: the impact of genomics on disease control. 6th ClostPath International Conference; 2009 19-23 Oct; Rome. Rome: Local Organizer Secretariat, 2009: 69. (Abstract No. P11). http://www.clostridia.net/rome/ClostPath2009-abstract-book.pdf (accessed Dec 2010).
  • 4. Riley TV. Epidemic Clostridium difficile. Med J Aust 2006; 185: 133-134. <MJA full text>
  • 5. Clements AC, Magalhaes RJ, Tatem AJ, et al. Clostridium difficile PCR ribotype 027: assessing the risks of further worldwide spread. Lancet Infect Dis 2010; 10: 395-404.
  • 6. Riley TV, Thean S, Hool G, Golledge CL. First Australian isolation of epidemic Clostridium difficile PCR ribotype 027. Med J Aust 2009; 190: 706-708. <MJA full text>
  • 7. Wallace L. Hospital circular 15/2010: identification of a hypervirulent strain of Clostridium difficile. Melbourne: State Government of Victoria Department of Health, 2010. http://www.health.vic.gov.au/hospitalcirculars/circ10/circ1510.htm (accessed Dec 2010).
  • 8. Goorhuis A, Bakker D, Corver J, et al. Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin Infect Dis 2008; 47: 1162-1170.
  • 9. Stuart RL, Marshall C, McLaws ML, et al. ASID/AICA position statement: infection control guidelines for patients with Clostridium difficile infection in health care settings. Healthcare Infect 2011. In press.
  • 10. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31: 431-455.
  • 11. Bauer MP, Kuijper EJ, van Dissel JT. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI). Clin Microbiol Infect 2009; 15: 1067-1079.
  • 12. Kuntz JL, Yang M, Cavanaugh J, et al. Trends in Clostridium difficile infection among peripartum women. Infect Control Hosp Epidemiol 2010; 31: 532-534.
  • 13. Knoop FC, Owens M, Crocker IC. Clostridium difficile: clinical disease and diagnosis. Clin Microbiol Rev 1993; 6: 251-265.
  • 14. Howell MD, Novack V, Grgurich P, et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med 2010; 170: 784-790.
  • 15. Thomas C, Stevenson M, Riley TV. Antibiotics and hospital-acquired Clostridium difficile-associated diarrhoea: a systematic review. J Antimicrob Chemother 2003; 51: 1339-1350.
  • 16. Hsu J, Abad C, Dinh M, Safdar N. Prevention of endemic healthcare-associated Clostridium difficile infection: reviewing the evidence. Am J Gastroenterol 2010; 105: 2327-2339.
  • 17. Pepin J, Saheb N, Coulombe MA, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005; 41: 1254-1260.
  • 18. Zilberberg MD, Tillotson GS, McDonald C. Clostridium difficile infections among hospitalized children, United States, 1997–2006. Emerg Infect Dis 2010; 16: 604-609.
  • 19. Bartlett JG, Gerding DN. Clinical recognition and diagnosis of Clostridium difficile infection. Clin Infect Dis 2008; 46 Suppl 1: S12-S18.
  • 20. Kawamoto S, Horton KM, Fishman EK. Pseudomembranous colitis: spectrum of imaging findings with clinical and pathologic correlation. Radiographics 1999; 19: 887-897.
  • 21. Mohan SS, McDermott BP, Parchuri S, Cunha BA. Lack of value of repeat stool testing for Clostridium difficile toxin. Am J Med 2006; 119: 356.e7-356.e8.
  • 22. Aichinger E, Schleck CD, Harmsen WS, et al. Nonutility of repeat laboratory testing for detection of Clostridium difficile by use of PCR or enzyme immunoassay. J Clin Microbiol 2008; 46: 3795-3797.
  • 23. Crobach MJ, Dekkers OM, Wilcox MH, Kuijper EJ. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): data review and recommendations for diagnosing Clostridium difficile infection (CDI). Clin Microbiol Infect 2009; 15: 1053-1066.
  • 24. Swindells J, Brenwald N, Reading N, Oppenheim B. Evaluation of diagnostic tests for Clostridium difficile infection. J Clin Microbiol 2010; 48: 606-608.
  • 25. Planche T, Aghaizu A, Holliman R, et al. Diagnosis of Clostridium difficile infection by toxin detection kits: a systematic review. Lancet Infect Dis 2008; 8: 777-784.
  • 26. Dreger LM, Gleason PP, Chowdhry TK, Gazzuolo DJ. Intermittent-dose metronidazole-induced peripheral neuropathy. Ann Pharmacother 1998; 32: 267-268.
  • 27. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45: 302-307.
  • 28. Kelly CP, LaMont JT. Clostridium difficile — more difficult than ever. N Engl J Med 2008; 359: 1932-1940.
  • 29. Pepin J, Valiquette L, Gagnon S, et al. Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027. Am J Gastroenterol 2007; 102: 2781-2788.
  • 30. Khan MY, Hall WH. Staphylococcal enterocolitis — treatment with oral vancomycin. Ann Intern Med 1966; 65: 1-8.
  • 31. Bolton RP, Culshaw MA. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut 1986; 27: 1169-1172.
  • 32. Baines SD, O’Connor R, Freeman J, et al. Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J Antimicrob Chemother 2008; 62: 1046-1052.
  • 33. Shannon-Lowe J, Matheson NJ, Cooke FJ, Aliyu SH. Prevention and medical management of Clostridium difficile infection. BMJ 2010; 340: c1296.
  • 34. Apisarnthanarak A, Razavi B, Mundy LM. Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: case series and review of the literature. Clin Infect Dis 2002; 35: 690-696.
  • 35. Herpers BL, Vlaminckx B, Burkhardt O, et al. Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection. Clin Infect Dis 2009; 48: 1732-1735.
  • 36. Nelson R. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev 2007; (3): CD004610.
  • 37. Keighley MR, Burdon DW, Arabi Y, et al. Randomised controlled trial of vancomycin for pseudomembranous colitis and postoperative diarrhoea. Br Med J 1978; 2: 1667-1669.
  • 38. Lagrotteria D, Holmes S, Smieja M, et al. Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile-associated diarrhea. Clin Infect Dis 2006; 43: 547-552.
  • 39. Lowy I, Molrine DC, Leav BA, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010; 362: 197-205.
  • 40. de Lalla F, Nicolin R, Rinaldi E, et al. Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea. Antimicrob Agents Chemother 1992; 36: 2192-2196.
  • 41. Wullt M, Odenholt I. A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile-associated diarrhoea. J Antimicrob Chemother 2004; 54: 211-216.
  • 42. O’Neill GL, Beaman MH, Riley TV. Relapse versus reinfection with Clostridium difficile. Epidemiol Infect 1991; 107: 627-635.
  • 43. Lamontagne F, Labbe AC, Haeck O, et al. Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain. Ann Surg 2007; 245: 267-272.
  • 44. Noblett SE, Welfare M, Seymour K. The role of surgery in Clostridium difficile colitis. BMJ 2009; 338: b1563.
  • 45. Gustafsson A, Lund-Tonnesen S, Berstad A, et al. Faecal short-chain fatty acids in patients with antibiotic-associated diarrhoea, before and after faecal enema treatment. Scand J Gastroenterol 1998; 33: 721-727.
  • 46. Aas J, Gessert CE, Bakken JS. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis 2003; 36: 580-585.
  • 47. Silverman MS, Davis I, Pillai DR. Success of self-administered home fecal transplantation for chronic Clostridium difficile infection. Clin Gastroenterol Hepatol 2010; 8: 471-473.
  • 48. Pillai A, Nelson R. Probiotics for treatment of Clostridium difficile-associated colitis in adults. Cochrane Database Syst Rev 2008; (1): CD004611.
  • 49. McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994; 271: 1913-1918.
  • 50. Enache-Angoulvant A, Hennequin C. Invasive Saccharomyces infection: a comprehensive review. Clin Infect Dis 2005; 41: 1559-1568.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.